Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE and lenvatinib with or without toripalimab for advanced unresectable hepatocellular carcinoma
ChiCTR2000033668Phase 2Not yet recruiting
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing TACE + lenvatinib + toripalimab with TACE + lenvatinib (2 arms). Primary endpoints: objective response rate, duration of response and 3 more. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
lenvatinibtoripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000033668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033668.